Endo Pharmaceuticals has announced the successful clinical results from a Phase II study of axomadol, a drug to treat moderate-to-severe chronic low back pain.
The drug was orally administered at doses ranging from 100mg a day to 300mg a day over a four-week period, with a 12-week maintenance phase.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The randomised, double blind, placebo-controlled and parallel group study included 236 patients and showed a change in average pain intensity from baseline.
